ROLES OF BIOSIMILARS ON PATIENT ACCESS
Author(s)
Laszlo Gulacsi, DSc, Corvinus University of Budapest, Budapest, Hungary; Jørgen Jahnsen, Ph.D, Akershus University Hospital, Lørenskog, Norway; HoUng Kim, MBA, Celltrion Healthcare, Incheon, Korea, Republic of (South); Edmund J. Pezalla, MD, PhD, MPH, Aetna, Wethersfield, USA
Presentation Documents
Many studies demonstrate the clinical benefits of biologics in the early phases of autoimmune diseases. However, only a limited number of patients have access to the treatments due to their high-cost. The role of biosimilars is to make necessary biologic treatments more affordable and available to those needing treatment. We will discuss and compare the use of biosimilars in Europe and the US.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Topic
Health Policy & Regulatory, Specialized Treatment Areas